BHC Stock Analysis: Bausch Health Companies | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 2.252m USD | 12M Return: 17% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.67M
EPS Trend: 84.9%
Qual. Beats: 1
Rev. Trend: 99.6%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bausch Health Companies Inc. (BHC) is a Canadian-headquartered, diversified specialty pharmaceutical and medical device company that operates through five reporting segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Its product portfolio spans a broad set of therapeutic areas, including gastroenterology, hepatology, neurology, dermatology, generic and branded generic pharmaceuticals, dentistry, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The geographic footprint is wide, with sales across the United States, Canada, China, Mexico, several major European markets (France, Germany, the UK, Spain, Italy, Poland), and select Asia-Pacific and other international regions.
The company was originally known as Valeant Pharmaceuticals International, Inc. and rebranded as Bausch Health Companies Inc. in July 2018; it has been publicly listed since 1994. As a small-cap healthcare name (market capitalization of approximately $1.86 billion USD) classified within the GICS Pharmaceuticals sub-industry, BHCs business model combines prescription specialty drugs, generics, consumer health products, and medical devices-a structure typical of diversified pharma companies that balance higher-margin specialty therapeutics with volume-driven generics and OTC franchises. Its Bausch + Lomb segment also gives the company a meaningful position in the global eye health market, one of the larger and more defensible niches within healthcare, while its aesthetic medical device operations place it within the growing medical aesthetics sector.
- Bausch + Lomb stake value drives equity narrative
- Salix Xifaxan cash flow funds aggressive debt paydown
- High leverage and ongoing litigation cap multiple expansion
- International segment faces FX and pricing pressure
| Net Income: -1.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 1.63 > 0.02 and ΔFCF/TA 159.3 > 1.0 |
| NWC/Revenue: -30.29% < 20% (prev 15.55%; Δ -45.84% < -1%) |
| CFO/TA 2.00 > 3% & CFO 1.80b > Net Income -1.08b |
| Net Debt (20.3b) to EBITDA (3.92b): 5.19 < 3 |
| Current Ratio: 0.22 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (375.0m) vs prev 1.90% < -2% |
| Gross Margin: 71.99% > 18% (prev 65.49%; Δ 6.50% > 0.5%) |
| Asset Turnover: 76.72% > 50% (prev 36.29%; Δ 40.43% > 0%) |
| Interest Coverage Ratio: 1.68 > 6 (EBIT TTM 2.69b / Interest Expense TTM 1.61b) |
| A: -3.64 (Total Current Assets 900.0m - Total Current Liabilities 4.17b) / Total Assets 900.0m |
| B: -10.72 (Retained Earnings -9.65b / Total Assets 900.0m) |
| C: 0.19 (EBIT TTM 2.69b / Avg Total Assets 14.1b) |
| D: -0.02 (Book Value of Equity -553.0m / Total Liabilities 25.9b) |
| Altman-Z'' = -57.54 = D |
As of August 01, 2026, the stock is trading at USD 6.89 with a total of 16,939,823 shares traded. Over the past week, the price has changed by +55.53%, over one month by +39.76%, over three months by +20.45% and over the past year by +16.98%.
Current recommended Stop Loss: 6.50 (which is 5.7% or 1.4 ATR below the current price).
Bausch Health Companies has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold BHC.
- StrongBuy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 7.5 | 8.9% |
P/E Forward = 1.0641
P/S = 0.2139
P/B = 18.7773
P/EG = 0.011
Revenue TTM = 10.8b USD
EBIT TTM = 2.69b USD
EBITDA TTM = 3.92b USD
Long Term Debt = 20.6b USD (from longTermDebt, last fiscal year)
Short Term Debt = 296.5m USD (from shortTermDebt, last fiscal year)
Debt = 21.2b USD (from shortLongTermDebtTotal, last fiscal year) + Leases 31.0m
Net Debt = 20.3b USD (calculated: Debt 21.2b - CCE 900.0m)
Enterprise Value = 22.6b USD (2.25b + Debt 21.2b - CCE 900.0m)
Interest Coverage Ratio = 1.68 (Ebit TTM 2.69b / Interest Expense TTM 1.61b)
EV/FCF = 15.36x (Enterprise Value 22.6b / FCF TTM 1.47b)
FCF Yield = 6.51% (FCF TTM 1.47b / Enterprise Value 22.6b)
FCF Margin = 13.61% (FCF TTM 1.47b / Revenue TTM 10.8b)
Net Margin = -10.02% (Net Income TTM -1.08b / Revenue TTM 10.8b)
Gross Margin = 71.99% ((Revenue TTM 10.8b - Cost of Revenue TTM 3.03b) / Revenue TTM)
Gross Margin QoQ = none% (prev 61.21%)
Tobins Q-Ratio = 25.10 (Enterprise Value 22.6b / Total Assets 900.0m)
Interest Expense / Debt = 7.57% (Interest Expense 1.61b / Debt 21.2b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 2.13b (EBIT 2.69b * (1 - 21.00%))
Current Ratio = 0.22 (Total Current Assets 900.0m / Total Current Liabilities 4.17b)
Debt / Equity = -38.41 (negative equity) (Debt 21.2b / totalStockholderEquity, last fiscal year -553.0m)
Debt / EBITDA = 5.19 (Net Debt 20.3b / EBITDA 3.92b)
Debt / FCF = 13.83 (Net Debt 20.3b / FCF TTM 1.47b)
Total Stockholder Equity = -985.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.68% (Net Income -1.08b / Total Assets 900.0m)
RoE = 109.8% (negative equity) (Net Income TTM -1.08b / Total Stockholder Equity -985.1m)
RoCE = 13.73% (EBIT 2.69b / Capital Employed (Equity -985.1m + L.T.Debt 20.6b))
RoIC = -60.50% (NOPAT 2.13b / Invested Capital -3.52b)
WACC = 6.37% (E(2.25b)/V(23.5b) * Re(10.09%) + D(21.2b)/V(23.5b) * Rd(7.57%) * (1-Tc(0.21)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.62 | Cagr: 0.91%
[DCF] Terminal Value 77.97% ; FCFF base≈1.32b ; Y1≈1.52b ; Y5≈2.23b
[DCF] Fair Price = 35.52 (EV 33.6b - Net Debt 20.3b = Equity 13.3b / Shares 373.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.86 | EPS CAGR: 5.69% | SUE: 2.32 | # QB: 1
Revenue Correlation: 99.56 | Revenue CAGR: 8.48% | SUE: 1.93 | # QB: 3
EPS current Quarter (2026-09-30): EPS=1.13 | Chg30d=-11.98% | Revisions=-40% | Analysts=4
EPS current Year (2026-12-31): EPS=4.30 | Chg30d=-2.71% | Revisions=+25% | GrowthEPS=+14.8% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=3.88 | Chg30d=-7.92% | Revisions=+40% | GrowthEPS=-9.7% | GrowthRev=-0.4%
[Analyst] Revisions Ratio: +12% (up=3, down=2)